Indications for: PLEGRIDY
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
See full labeling. May give by SC inj in abdomen, back of the upper arm, or by SC or IM inj in thigh(s). Rotate inj sites. Initially 63mcg on Day 1, increase to 94mcg on Day 15, then 125mcg on Day 29 and every 14 days thereafter. May give analgesics and/or antipyretics for flu-like symptoms. Switching between SC and IM inj or vice versa has not been studied.
Depression. Suicidal ideation. Consider discontinuing if depression or other severe psychiatric symptoms occur. Seizure disorder. Discontinue if serious allergic reactions occur. Significant cardiac disease; monitor for worsening condition at initiation and during treatment. Risk of thrombotic microangiopathy; discontinue if occurs. Monitor for hepatic injury, infections, bleeding, anemia. Myelosuppression. Obtain CBCs with differential and platelets during treatment. Consider discontinuing if new autoimmune disorder develops. Latex allergy (IM syringe cover). Severe renal impairment: monitor. Pregnancy. Nursing mothers.
Inj site reactions (erythema, pain, pruritus), influenza-like illness, pyrexia, headache, myalgia, chills, asthenia, arthralgia; hepatic injury, seizures, CHF, hematologic or autoimmune disorders, inj site necrosis (suspend if multiple lesions occur until healed); rare: allergic reactions.
To enroll women exposed to Plegridy during pregnancy call (866) 810-1462 or visit https://www.plegridypregnancyregistry.com/.
Generic Drug Availability:
For SC: single-dose prefilled pens (125mcg/0.5mL)—2; single-dose prefilled syringes (125mcg/0.5mL)—2; Starter Pack (pens and syringes)—2 (63mcg/0.5mL + 94mcg/0.5mL); For IM: single-dose prefilled syringes (125mcg/0.5mL)—2; Titration Kit (syringes)—2 (63mcg/0.5mL + 94mcg/0.5mL)